📰 Pharmaceutical Intelligence News
Page 3 - Pharmaceutical Intelligence News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pharmaceutical Intelligence. Real-time updates on events, politics, business and more.
November 4, 2023
ATH-399A is under clinical development by NurrOn Pharmaceuticals and currently in Phase I for Parkinson's Disease.
October 28, 2023
CLN-619 is under clinical development by Cullinan Oncology and currently in Phase I for Colon Cancer.
October 28, 2023
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Cancer.
October 28, 2023
KB-0742 is under clinical development by Kronos Bio and currently in Phase II for Ewing Sarcoma.
October 28, 2023
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Primary CNS Lymphoma.
October 28, 2023
Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas.
October 28, 2023
Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).
October 28, 2023
(IO-102 + IO-103) is under clinical development by IO Biotech and currently in Phase II for Lung Adenocarcinoma.
October 28, 2023
OBI-999 is under clinical development by OBI Pharma and currently in Phase II for Breast Cancer.
October 28, 2023
AGEN-2373 is under clinical development by Agenus and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC).